Shang Hai Zheng Quan Bao·2025-11-27 23:11Core Viewpoint - China CNR Corporation plans to spin off its subsidiary, CRRC Qishuyan Locomotive and Rolling Stock Research Institute Co., Ltd. (referred to as "CRRC Qishuyan"), for listing on the Shenzhen Stock Exchange's ChiNext board, which will not affect the company's ownership structure and control over CRRC Qishuyan [1][3]. Group 1: Spin-off Details - The spin-off requires approval from the company's shareholders and compliance with relevant procedures from the stock exchange and the China Securities Regulatory Commission [3]. - The spin-off aims to enhance business focus, allowing China CNR to concentrate on its core sectors, including railway equipment, urban rail and infrastructure, new industries, and modern services [4][5]. - After the spin-off, CRRC Qishuyan will remain a controlled subsidiary within the consolidated financial statements of China CNR, meaning its financial performance will still impact the parent company's overall financials [4][5]. Group 2: Financial Performance and Market Position - CRRC Qishuyan, established in 1992, specializes in high-end equipment key components and system solutions, with products covering rail transit equipment, energy and engineering equipment, automotive parts, and intelligent manufacturing [8]. - According to unaudited financial data, CRRC Qishuyan is projected to achieve a net profit attributable to the parent company of 308 million yuan in 2024 [8]. - The spin-off is expected to strengthen CRRC Qishuyan's capital base and business development capabilities, enhancing its market competitiveness and expanding its business layout, which will benefit the overall profitability of China CNR in the long run [5][8]. Group 3: Industry Trends - The trend of spin-offs is gaining momentum, with nearly 30 A-share listed companies planning similar actions since 2025, primarily in high-tech industries such as information technology and advanced equipment manufacturing [10]. - Other companies, such as China Unicom and Zhejiang Pharmaceutical, are also pursuing spin-offs to enhance their operational capabilities and market presence [10][12].